Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole in Psychosis Associated with Alzheimer's Dementia
NCT00036114Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2000
- Primary completion
- Aug 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole in Alzheimer's disease (AD) (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Neuropsychiatric Inventory-Nursing Home Version Psychosis Subscale at 10 weeks. Started Mar 2000; status: completed.
02
Drugs
aripiprazole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00036114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036114.